WuXi Biologics (Cayman) Inc., a global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the approval of its near-term and net-zero greenhouse gas emissions reduction targets by the Science Based Targets initiative (SBTi). The company aims to achieve net-zero emissions across its value chain by 2050, aligning with the 1.5°C mitigation pathways. WuXi Biologics' integrated strategy includes measurable targets for emissions reduction, with its efforts recognized by several organizations, including an MSCI AAA Rating, EcoVadis Platinum Medal, and listing in the Dow Jones Sustainability Indices. The company is also a participant in the United Nations Global Compact and Pharmaceutical Supply Chain Initiative.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN61029) on August 28, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.